Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Inclusion Criteria

• Age ≥18 years
• Planned SoC SBRT as definitive treatment
• World Health Organization (WHO)/ECOG PS of 0, 1 or 2
• Life expectancy of at least 12 weeks
• Body weight >30 kg
• Submission of tumor tissue sample if available
• Adequate organ and marrow function required
• Patients with central or peripheral lesions are eligible
• Staging studies must be done during screening (PET-CT within 10 weeks)
• Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions Main Cohort Key

Exclusion Criteria

• Mixed small cell and non-small cell cancer
• History of allogeneic organ transplantation
• History of another primary malignancy with exceptions
• History of active primary immunodeficiency
• Epidermal growth factor receptor local testing is strongly recommended prior to enrollment. Patients with a tumor harboring an EGFRm per local testing will be excluded from the main cohort
• Prior exposure to immune-mediated therapy with exceptions Osimertinib Cohort Key